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Summary Panton-Valentine leukocidin (PVL) is a two-component toxin associ-
ated with the toxicity and virulence of Staphylococcus aureus. The presence of
PVL is well documented in community-acquired methicillin-resistant S. aureus (CA-
MRSA) and is observed in methicillin-susceptible S. aureus (MSSA) with variable
prevalence. We assessed the prevalence of PVL in a sample of 93 MSSA patients
in a healthcare facility in Eastern Saudi Arabia using real-time PCR for lukSF-PV
genes. The presence or absence of PVL was correlated with age, gender, hospi-
talization status, infection site and antibiotic resistance. PVL was detected in 28
(30%) patient samples. PVL was associated with a greater likelihood of resistance
to trimethoprim—sulfamethoxazole (a resistance of 39.2% of PVL-positive isolates
compared to 6.1% of PVL-negative isolates) (p < 0.0007). These results suggest a sig-
niﬁcant prevalence of PVL expression in MSSA strains in the study population and
call for monitoring of and surveillance programs for PVL status and the selection of
appropriate antibiotic treat
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taphylococcus aureus are nasal, commensal Gram-
ositive cocci, which colonize in 20—30% of the
uman population [1], as well as livestock and
omestic animals [2,3]. As a human pathogen, S.
ureus causes infections ranging from mild skin
nd soft tissue infections to life-threatening sepsis,
neumonia, and toxic shock syndrome. S. aureus
athophysiology depends on the presence of viru-
ence factors, including those present on the cell
urface and secreted factors. One virulence factor
ssociated with S. aureus toxicity is the Panton-
alentine leukocidin (PVL), a two-component toxin
hat acts by forming pores in the mitochondria [4].
he dual leukocidin PVL toxin components, LukS
nd LukF, are encoded by the adjacent prophage
ukS and lukF genes [5,6]. PVL reduces immune
esistance in a number of ways; for example, it
auses neutrophil lysis or apoptosis [4,7] and tar-
ets complement receptors [8]. In humans, PVL
s associated with skin and soft tissue infections
SSTI), bone and joint infections and necrotizing
neumonia [9]. PVL has been linked to exacerbation
f bone loss in osteomyelitis [10] and is proposed as
n important virulence factor in keratitis associated
ith S. aureus infection [11].
The prevalence of PVL in methicillin-resistant
. aureus (MRSA) is well documented. It is
ighly expressed in community-acquired (CA)-MRSA
trains. However, PVL is expressed in healthcare-
ssociated (HA)-MRSA. PVL is a relatively stable
arker of CA-MRSA and is associated in particu-
ar with the staphylococcal cassette chromosomes
SCCmec) types IV and V [5,6,12]. The role of PVL
n CA-MRSA virulence is debated. In humans, it is
ssociated with increased virulence [6], but animal
tudies have yielded conﬂicting results, with a pos-
ible immunomodulatory role suggested beyond the
ytotoxic effects [13—15].
PVL has also been observed in methicillin-
usceptible S. aureus (MSSA) strains. Although the
pidemiology has not been as extensively estab-
ished as in MRSA, recently, interest has increased in
his ﬁeld of research. PVL prevalence in MSSA infec-
ions varies between countries, from low levels
0.7—2.9%) in Northern Spain, Ireland and Portugal
16—18] to 37% in New Zealand and even higher in
frican countries, such as Nigeria [19], Cameroon,
adagascar, Morocco, Niger, and Senegal [20]. PVL-
ositive MSSA has been associated with SSTI [21,22]
nd cases of necrotizing pneumonia [23,24]. Risk
actors for PVL-positive MSSA include Paciﬁc ethnic-
ty, young age, SSTI diagnosis, community-acquired
nset of infection, need for surgical intervention,
rior hospitalization and smoking [21,25,26].
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Because of the wide variation in incidence of
VL-positive MSSA between countries, it is impor-
ant to characterize MSSA PVL prevalence and
isk factors in Saudi Arabia. No such compre-
ensive analysis has been performed previously,
lthough an isolated case of PVL-positive MSSA was
eported in a child with acute osteomyelitis [27]
nd among 37.6% of 101 MRSA isolates in Jeddah
28]. This study presents data on PVL prevalence in
3 patients with MSSA from a healthcare facility in
he Eastern Province of Saudi Arabia.
aterials and methods
acterial isolates
total of 93 MSSA clinical isolates were randomly
ollected from the Dhahran Health Center, Microbi-
logy Section, from January until December 2013.
hese specimens were obtained at the request of
he attending physician for clinical reasons. The
dentiﬁcation of the strains and antibiotics pro-
les were performed using the VITEK II system.
he isolates were sent to the molecular diagnostic
aboratory for PVL gene testing. Each isolate was
solated from a different patient.
NA extraction
enomic DNA was extracted using the Roche MagNa
ure compact nucleic acid isolation kit I, DNA
acteria protocol, according to the manufacturer
nstructions. Brieﬂy, each strain was resuspended
n 0.2ml of 0.85% saline.
etection of lukS PV gene
he extracted DNA was screened with the TIB-
OLBIOL LightMix® CA-MRSA PCR kit, Cat# 40-0325-
6.
linical data
lectronic clinical records were reviewed to ascer-
ain the following demographic data: patient age,
ender, and hospitalization.
esults
SSA isolates were obtained from a total of 93
atients with an age range of 11 months to 99 years.
ost infections (72%) were obtained from sputum,
lood, semen or urine samples, catheter-related
nfections, wounds or abscesses. The patients were
366 A.M. Bazzi et al.
Table 1 Antibiotic-resistance pattern of all isolates and PVL positive and PVL negative isolates.
Number resistance
(%), N = 93
Resistance (%)
among PVL+, N = 28
Number resistance (%)
among PVL−, N = 65
Penicillin 82 (88.17) 28 (100) 54 (83)
Oxacillin 0 (0) 0 (0) 0 (0)
Gentamicin 1 (1.07) 1 (3.6) 0 (0)
Ciproﬂoxacin 16 (17.02) 7 (25) 9 (13.8)
Levoﬂoxacin 15 (16.3) 7 (25) 8 (12.3)
Moxiﬂoxacin 15 (16.3) 7 (25) 8 (12.3)
Erythromycin 9 (9.6) 3 (10.7) 6 (9.2)
Clindamycin 2 (2.15) 0 (0) 2 (3)
Quinupristin 0 (0) 0 (0) 0 (0)
Linezolid 0 (0) 0 (0) 0 (0)
Vancomycin 0 (0) 0 (0) 0 (0)
Tetracycline 7 (8.6) 2 (7.1) 5 (7.6)
Tigecycline 0 (0) 0 (0) 0 (0)
Nitrofurantoin 0 (0) 0 (0) 0 (0)
Rifampicin 0 (0) 0 (0) 0 (0)
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dTrimethoprim—sulfamethoxazole 14 (15)
divided almost equally between those who were
(48.4%) or were not (51.6%) hospitalized during
the previous year. The antibiogram of the isolates
is shown in Table 1. Most isolates were resistant
to penicillin (88.75%), and all were susceptible to
oxacillin, quinupristin, linezolid, tigecycline, nitro-
furantoin and rifampicin.
PVL presence or absence was conﬁrmed by real-
time PCR for lukSF-PV genes. PVL was detected in
28 of 93 samples (30%). Table 2 shows the results
of the univariate analysis to compare features of
PVL-positive to PVL-negative MSSA. A signiﬁcantly
higher proportion of PVL-negative subjects were
aged between 50 and 59 years (33.9%) compared
to the PVL-positive patients (10.7%) (p = 0.023)
(Table 2). Of all PVL positive patients, seven (25%)
were aged 0—9 years, two (7.1%) were aged 10—19
years, six (21.4%) were aged 20—29 years, four
(14.2%) were aged 40—49 years, and three (10.7%)
were aged 50—59 years (Table 2).
Resistance to trimethoprim—sulfamethoxazole
showed a strong association with PVL-positivity, and
39.2% of PVL-positive isolates were resistant com-
pared to 6.1% of PVL-negative isolates (p = 0.0007)
(Table 2). No other antibiotic resistance proﬁle
showed any association with PVL positivity (data
not shown). Gender, hospitalization status or site
of infection was not associated with PVL positivity
(Table 2).Discussion
The results showed that the prevalence of PVL in
MSSA infections in this study was 30%. This ﬁnding
a
F
a
a12 (42.8) 2 (3)
s similar to reports for PVL-positive MSSA preva-
ence in Auckland, New Zealand [21] and in the
rkhangelsk region of Russia [29]. It is signiﬁcantly
igher than the reported prevalence in Northern
pain, Queensland, Australia, Ireland and Portugal
16—18,30], and lower than the rate in African
ountries, in particular Cameroon, Niger, and
enegal [20].
Previous studies showed that risk factors for PVL
resence in MSSA strains include younger age and
rior hospitalization [21,25,30]. Similarly, in the
urrent study, PVL positivity is associated with a
ounger age (0—29 years) and prior hospitalization.
For antibiotic resistance, the majority
88.75%) of isolates were resistant to peni-
illin. Of the 15 isolates that were resistant to
rimethoprim—sulfamethoxazole, 11 were PVL-
ositive. This represents 39.2% of PVL-positive
solates compared to 6.1% of PVL-negative iso-
ates. Trimethoprim-sulfamethoxazole resistance
ay represent the spread of a speciﬁc clone in
ur locality. This trend for the association of
rimethoprim—sulfamethoxazole with PVL should
e further examined.
The current study has a relatively small sample
ize and did not characterize samples according to
ndividual infection groups, nor did it consider fac-
ors such as ethnicity or social deprivation, which
nﬂuence PVL association with MSSA according
o other studies [21]. Therefore, the sample size
oes not produce (with conﬁdence) a signiﬁcant
ssociation with the investigated risk factors.
urther studies should increase the sample size
nd consider other potential contributory factors
nd should investigate the association between
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rimethoprim-sulfamethoxazole resistance and
VL. In addition, it is necessary to assess large
umbers of patients, with an emphasis on risk fac-
ors/groups. These factors include close contact,
uch as sports and crowding, and skin abrasion,
leanliness, or item sharing. The authors advocate
tandardized surveillance procedures for S. aureus
nfections in the region and mindfulness of the
otential contribution of PVL to MSSA as well as
RSA virulence. Trends indicated by this study
uggest that the presence of PVL should inﬂuence
he selection of antibiotic treatment, particularly
n the case of trimethoprim—sulfamethoxazole.
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